Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)
Department of Health and Human Services
The purpose of this Notice of Funding Opportunity (NOFO) is to invite applications that bundle independent protocols for phase 1 clinical trials with phase 1b/phase 2a clinical trials to streamline the early-stage evaluation of promising pharmacological interventions for Alzheimer's disease (AD) and Alzheimer's disease-related Dementias (ADRD). Candidate interventions evaluated through this program, which can include small molecules or biologics for example, must engage non-amyloid/non-tau mechanisms and aim to address cognitive and/or neuropsychiatric symptoms in individuals across the spectrum from pre-symptomatic to more severe stages of disease. This NOFO uses the UG3/UH3 phased award me
Funding
Award size
Not specified
Type
Cooperative Agreement
Dates
Deadline
Later
Posted
11/22/2024
Closes
2026-11-19
Eligibility
Eligibility
Others (see text field entitled "Additional Information on Eligibility" for clarification)For profit organizations other than small businessesPublic housing authorities/Indian housing authoritiesCounty governmentsPrivate institutions of higher educationNonprofits having a 501(c)(3) status with the IRS, other than institutions of higher educationNative American tribal governments (Federally recognized)State governmentsPublic and State controlled institutions of higher educationNonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher educationIndependent school districtsCity or township governmentsSpecial district governmentsSmall businessesNative American tribal organizations (other than Federally recognized tribal governments)
Program
Funding area
Health - HL
Opportunity #
PAR-25-226
Source
Status
Open
Market
Government
Level
Federal
Source
Grants.gov